Malta - engleski - Medicines Authority

sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 100 mg - antimycotics for systemic use

Malta - engleski - Medicines Authority

ebewe pharma gmbh nfg. kg - oxaliplatin 5 mg/ml - powder for solution for infusion

Australija - engleski - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - hydrocortisone sodium succinate, quantity: 133.7 mg - injection, powder for - excipient ingredients: dibasic sodium phosphate; monobasic sodium phosphate - when oral therapy is not feasible, and the strength, form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, hydrocortisone panpharma powder for injection is indicated for intravenous or intramuscular use in the following conditions:,1. endocrine disorders ? primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogues may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplements may be necessary, particularly when synthetic analogues are used). ? preoperatively and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful ? shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected ? congenital adrenal hyperplasia ? nonsuppurative thyroiditis ? hypercalcaemia associated with cancer. 2. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: ? post-traumatic osteoarthritis ? synovitis of osteoarthritis ? rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) ? acute and subacute bursitis ? epicondylitis ? acute nonspecific tenosynovitis ? acute gouty arthritis ? psoriatic arthritis ? ankylosing spondylitis.,3. collagen diseases during an exacerbation or as maintenance therapy in selected cases of: ? systemic lupus erythematosus ? systemic dermatomyositis (polymyositis) ? acute rheumatic carditis.,4. dermatological diseases ? pemphigus ? severe erythema multiforme (stevens-johnson syndrome) ? exfoliative dermatitis ? bullous dermatitis herpetiformis ? severe seborrhoeic dermatitis ? severe psoriasis ? mycosis fungoides.,5. allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: ? bronchial asthma ? drug hypersensitivity reactions ? contact dermatitis ? urticarial transfusion reactions ? atopic dermatitis ? serum sickness ? seasonal or perennial allergic rhinitis ? acute noninfectious laryngeal oedema (adrenaline is the drug of first choice).,6. ophthalmic diseases severe acute and chronic allergic and inflammatory processes involving the eye, such as: ? herpes zoster ophthalmicus ? iritis, iridocyclitis ? chorioretinitis ? diffuse posterior uveitis and choroiditis ? optic neuritis ? sympathetic ophthalmia ? anterior segment inflammation ? allergic conjunctivitis ? allergic corneal marginal ulcers ? keratitis.,7. gastrointestinal diseases to tide the patient over a critical period of the disease in: ? ulcerative colitis (systemic therapy) ? regional enteritis (systemic therapy).,8. respiratory diseases ? symptomatic sarcoidosis ? loeffler's syndrome not manageable by other means ? berylliosis ? fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy ? aspiration pneumonitis.,9. haematological disorders ? acquired (autoimmune) haemolytic anaemia ? erythroblastopenia (rbc anaemia) ? idiopathic thrombocytopenic purpura in adults (iv only; im administration is contraindicated) ? secondary thrombocytopenia in adults ? congenital (erythroid) hypoplastic anaemia.,10. neoplastic diseases for palliative management of: ? leukaemias and lymphomas in adults ? acute leukaemia in childhood.,11. oedematous states ? to induce diuresis or remission of proteinuria in the nephrotic syndrome, without uraemia, of the idiopathic type or that due to lupus erythematosus.,12. miscellaneous ? tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy ? trichinosis with neurological or myocardial involvement.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - glucose, quantity: 500 mg/ml - injection, intravenous infusion - excipient ingredients: hydrochloric acid; water for injections; sodium bicarbonate - glucose 50% intravenous infusion is strongly hypertonic and may be used to reduce increased cerebrospinal pressure and/or oedema due to delirium tremens or acute alcoholic intoxication. it may also be used to treat severe hypoglycaemia due to an excess of insulin and to provide concentrated calories in total parenteral nutrition regimes.

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram

Velika Britanija - engleski - MHRA (Medicines & Healthcare Products Regulatory Agency)

dendron brands ltd - sodium chloride; potassium chloride; sodium citrate; rice powder pre-cooked - powder for oral solution - 350mg ; 300mg ; 580mg ; 6gram

Australija - engleski - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - 32172 - infusion stopcock - for use in intravascular or arterial lines for injection or removal of fluids

Australija - engleski - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - 32172 - infusion stopcock - this device is for use in intravascular or arterial lines to regulate fluid delivery to a patient's vascular system.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - 66701 - infusion pump lock box - this device is intended to avoid misuse of a drug, as deemed necessary, by preventing unauthorized access to the pump console or medications whilst the pump is in use.

Australija - engleski - Department of Health (Therapeutic Goods Administration)

becton dickinson pty ltd - 35833 - electric infusion pump administration set - to deliver fluid or drug from a bag to a patient, used with an infusion pump.